Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015839
Chunk: 85

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 85
---
 income for the three and six months ended June 30, 2025 relates to interest income earned on short-term money market investments. Interest expense, net was $79,025 for the three and six months ending June 30, 2024, related to interest on convertible note payables.

Change in fair value of Debentures was $200,000 for both the three and six months ending June 30, 2025. The $200,000 relates to the remeasurement of the Debentures at fair value at the reporting date.

The following table outlines our statements of loss and comprehensive loss for the years ended December 31, 2024 and 2023:

|                                               |     | Years ended December 31, |   |     |            |   |     |            |   |
|                                               |     |                     2024 
                        $ |   |     |       2023 
          $ |   |     |     Change |   |
| General and administrative                    |     |                7,653,116 |   |     |  4,536,367 |   |     |  3,116,749 |   |
| Research and development                      |     |                3,527,786 |   |     |    193,578 |   |     |  3,334,208 |   |
| Total operating expenses                      |     |               11,180,902 |   |     |  4,729,945 |   |     |  6,450,957 |   |
| Loss from operations                          |     |              (11,180,902 | ) |     | (4,729,945 | ) |     | (6,450,957 | ) |
| Finance (income) expense, net                 |     |                  (25,386 | ) |     |    584,820 |   |     |   (610,206 | ) |
| Net loss and comprehensive loss               |     |              (11,155,516 | ) |     | (5,314,765 | ) |     |  5,840,751 |   |
| Net loss per common share (basic and diluted) |     |                    (1.16 | ) |     |      (1.53 | ) |     |            |   |

General and administrative

General and administrative expenses for the years ended December 31, 2024 and 2023 are comprised of: